Press Releases
Company announcements and regulatory disclosures.
Follow Curasight’s progress
Access company announcements, scientific and investor events, presentations and subscription options.
As a listed clinical-stage company, Curasight communicates material developments through formal market announcements.
Latest press releases
Press release archive
All
About Curasight
Curasight A/S is a clinical-stage radiopharmaceutical company developing products targeting uPAR, a target associated with aggressive cancer biology and a cancer target expressed across solid tumor types. The portfolio is organized through uTRACE®, the imaging and diagnostic platform, and uTREAT®, the therapeutic development platform comprising clinical stage glioblastoma programs and a next-generation uPAR-targeting ligand designed for modular alpha and beta payloads for additional solid tumor types.